September 14, 2020

 

 

 

VIA EDGAR

 

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

 

Attention:

Michael Fay

 

 

 

Daniel Gordon

 

 

 

Deanna Virginio

 

 

 

Ada D. Sarmento

 

 

 

 

 

 

Re:

Athira Pharma, Inc.

 

 

Registration Statement on Form S-1

 

 

File No. 333-248428 

 

 

Acceleration Request

 

 

Requested Date:  Thursday, September 17, 2020

 

 

Requested Time:  4 P.M. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Athira Pharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-248428) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Michael Nordtvedt at (206) 883-2524 or Bryan King at (206) 883-2535.

 

[Signature page follows]

 

 

 

 


 

 

Securities and Exchange Commission

September 14, 2020

Page 2

 

Sincerely,

ATHIRA PHARMA, Inc.

 

/s/ Leen Kawas

Leen Kawas

President and Chief Executive Officer

 

 

 

cc:

Glenna Mileson, Athira Pharma, Inc.

 

Michael Nordtvedt, Wilson Sonsini Goodrich & Rosati P.C.

 

Bryan D. King, Wilson Sonsini Goodrich & Rosati P.C.

 

Charles S. Kim, Cooley LLP

 

Alan D. Hambelton, Cooley LLP

 

Oren Lang-Furr, Ernst & Young LLP